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 ABBREVIATIONS 
 Confidence Interval (CI).
 Drug induced liver injury (DILI).
 High-income countries (HIC).
 Human immunodeficiency virus (HIV).
 Immune reconstitution inflammatory syndrome (IRIS).
 Interquartile range (IQR).
 Low to middle-income countries (LMIC).
 Odds Ratio (OR).
 Rifampicin, isoniazid, pyrazinamide & ethambutol (RHZE).
 Tuberculosis (TB).
DEFINITIONS 
 Adverse drug reaction (ADR) – a response to a medicine that is noxious and unintended
and occurs at doses normally used for the prophylaxis, diagnosis or therapy of disease, 
or for modification of physiological function. 
 Adverse event (AE) – any untoward medical occurrence in a patient, which does not
necessarily have a causal relationship with the administered medication. 
 Assent – a minor’s affirmation of their parent’s consent.
 Causality (assessment) – assessing the probability of a causal relationship between the
suspected causative medicine(s) and the observed adverse patient medical outcome(s). 
 Chart review – Review of medical notes, including prescriptions and laboratory reports.
 Child / paediatric patient – patients up to the age of 16.
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 Consent – agreeing to participate in the research study and have ones medical records 
reviewed, recorded and analysed for study purposes. 
 Disability – substantial disruption of a person's ability to conduct normal life functions 
or disruption in the patient's body function/structure, physical activities and/or quality 
of life. 
 Principal Investigator (PI) – The first author. 
 Seriousness – categorisation based on whether the patient’s outcome was “fatal, life 
threatening, necessitates hospitalisation, prolongs existing hospitalisation or results in 
persistent or significant disability or incapacity.” 
 Severity – categorisation of the ADR as per Hartwig severity scale (table 2) into mild, 
moderate and severe. 
 Type A ADR – augmented normal pharmacological action(s) of the drug which are 

















Purpose: Paediatric patients have more adverse drug reaction (ADR) rates than adults due to 
off-label use of medicines and the prevalence data of ADRs in Sub-Saharan African children 
is limited. The aim was to describe the prevalence and nature of ADRs in paediatric (≤ 16 years 
old) in-patients at a tertiary hospital in South Africa.  
Methods: We conducted a prospective study of paediatric in-patients to identify suspected 
ADRs. Children had to be admitted for at least 24 hours during the 3-month study period (1 
December 2015 to 29 February 2016). The data collected included age, sex, diagnosis and 
medicines received. We assessed causality using the 10-question Naranjo probability scale and 
classified severity using the Hartwig severity scale.  
Results: We found that 18.4% (52/282) of patients had 61 ADRs. The median age of patients 
with ADRs was 1.4 years (interquartile range (IQR): 0.5 – 5.3 years). ADR was the reason for 
admission in a third of the patients (31%; 16/52). Paediatric oncology patients suffered the  
majority of the ADRs (56.5%; 13/23), followed by HIV-infected patients on antiretroviral 
therapy (ART) (42.9%; 9/21) and tuberculosis (TB) patients (17.5%; 7/40). HIV-TB co-
infected patients also experienced a high 30.8% (4/13) rate of ADRs. The majority of the ADRs 
were moderate 45.9% (28/61), while 42.6% (26/61) were mild, and 11.5% severe ADRs (7/61). 
These ADRs range from severe neutropaenia 4.9% (3/61) and drug induced liver injury (DILI) 
4.9% (3/61) to mild cutaneous rashes 13.1% (8/61). There were no fatal ADRs, while 13.1% 
(8/61) ADRs were considered life threatening; 27.9% (17/61) necessitated and/or prolonged 
hospitalisation and 31.1% (19/61) resulted in persistent or significant disability or incapacity. 
Thirty eight percent of ADRs (23/61) were predictable. Paediatric oncology patients on 
chemotherapy were 7 times more likely to have ADR(s) than other patient groups [OR 7.3 (3.0 
– 17.9), p < 0.01]. More ADRs were associated with chemotherapy 44.3% (27/61) and 
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antimicrobials 42.6% (26/61), while the other miscellaneous medicine classes were associated 
with 34.4% (21/61) of the recorded ADRs. 
Conclusion: The prevalence of ADRs was 18.4% and in 31% the ADR was the reason for 
admission. The ADRs in paediatric oncology patients were expected, but of note nearly half 
the HIV-infected patients (43%) suffered an ADR. 























The World Health Organisation (WHO) defines an adverse drug reaction (ADR) as a response 
to a medicine that is noxious and unintended and occurs at doses normally used for the 
prophylaxis, diagnosis or therapy of disease, or for modification of physiological function.(1) 
The importance of ADRs has been documented by 4 systematic reviews conducted between 
1966 and 2012 in different paediatric therapeutic settings,(2–5) revealing that up to 39% of  
admissions are precipitated by ADRs often requiring more specialised care. However, the 
reported  prevalence of ADRs varies from country to country in both high income(6) and low to 
middle income countries.(7–9) Limited and recent data in the sub-Saharan Africa (SSA)(9) 
suggests a strong association between paediatric ADRs with the treatment of infectious 
diseases. Approximately 25%(10) of the world’s burden of human immunodeficiency virus 
(HIV)-tuberculosis (TB) co-infection is in South Africa, while the estimated annual risk of TB 
infection in children in the Western Cape Province ranges between 4% and 7%(11,12) per annum. 
TB and HIV co-infection necessitates polypharmacy, which poses as an important risk factor 
for ADRs.(2) Children in this setting may, therefore, have an inadequately documented 
increased risk of ADRs.   
Aims 
The primary objective was to determine the prevalence of ADRs in children admitted to 
Tygerberg hospital, a large tertiary hospital in South Africa. The secondary objectives were to 
determine the nature of the ADRs, assess causality and compare the prevalence of ADRs in the 
different patient sub-populations including patients with HIV, TB and/or cancer.   
 
 




We conducted a 3-month prospective observational study of paediatric patients admitted to 
Tygerberg hospital. This study utilised chart reviews alone. We included paediatric ( ≤16 years)  
in-patients admitted to Tygerberg hospital for at least 24 hours between 1 December 2015 and 
29 February 2016, whose parents gave informed consent (assent where relevant from the child 
participants). 
The principal investigator (PI) conducted comprehensive chart reviews of the records of study 
participants, who met the above inclusion criteria, on alternate days of the week to identify 
suspected ADRs on and during admission. These suspected ADRs were investigated, using the 
Naranjo probability scale, which is a validated causality assessment tool.(13) This scale (table 
1) answered 10 questions which were scored and used to categorise the probability of ADR 
causation into most probable (score ≥ 9), probable (score 5 – 8), possible (score 1 – 4) and 
doubtful (score ≤ 0). We excluded all (7) of the suspected ADRs that scored ≤ 0 on the Naranjo 
ADR scale (doubtful ADRs) from our ADR count. 
The Hartwig severity scale (table 2) was used to classify ADR severity(14) while the seriousness 
of the ADR was assessed in accordance with the International Conference on Harmonisation 
(ICH) and Council for International Organizations of Medical Sciences (CIOMS) definitions 
based on patient’s outcome. Seriousness was categorised based on whether the patient’s 
outcome was “fatal, life threatening, necessitates hospitalisation, prolongs existing 
hospitalisation or results in persistent or significant disability or incapacity.”(6)    
Tygerberg hospital is a 1384 bed tertiary hospital with 24% (n=331) paediatric beds.(15) The 
study was conducted in 4 of the 12 paediatric wards, excluding neonatology, surgical wards 
and the intensive care units. The four wards were identified and selected in conjunction with 
the Head of Department of Child Health and Paediatrics. Data collected included demographic 
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(age, sex) and clinical data, namely diagnosis, reason for admission, suspected ADR(s) and 
associated medication. In patients with suspected ADR(s), history of previous ADR diagnosis, 
dose response of the suspected ADR, alternative explanation(s) of the suspected ADRs as well 
as predisposing factors were recorded and captured on a Microsoft Excel (version 14) 
spreadsheet (annexure 1).  
Ethics 
The study was approved by the Stellenbosch Health Research Ethics Committee (Reference 
S15/08/171). The study was conducted in accordance with the 2013 Declaration of Helsinki, 
the South African Department of Health’s 2004 Guidelines as well as the South African Good 
Clinical Practice (SA-GCP) Guidelines.  Unique patient identification numbers were used to 
anonymity during data analysis and reporting.  
Statistical analysis  
The data was analysed, using Stata version 14.2 (Stata Corporation, College Station, TX).(16) 
Non-normally distributed data were described using medians and ranges. For descriptive 
analyses of patient characteristics and between patient groups, the chi-squared and Wilcoxon 
rank-sum (Mann-Whitney) tests were used. We used logistic regression analysis to evaluate 
covariates for occurrence of ADRs. We included all the study variables in the multivariate 
analysis and eliminated the non-statistically significantly associated variable via backward 
elimination. We expressed data as absolute numbers and percentages. We considered p-values 
< 0.05 to be statistically significant.  
Results  
A total of 305 patients were admitted for at least 24 hours, of whom 7.5% (23/305) declined 
consent to participate in the study. Of the 282 consenting patients (median age 1.4 years, range 
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9 days to 16.3 years, IQR 0.5 – 5.3 years), 18.4% (52/282) experienced at least one ADR. The 
underlying diagnosis was tuberculosis (TB) in 40, a cancer in 23 patients, 21 were HIV-infected 
and 13 had HIV-TB co-infection, while 198 had miscellaneous diagnoses. Of the 52 patients 
who experienced an ADR(s), 13 were paediatric oncology patients, 9 were HIV-infected, 7 had 
TB, 4 had HIV-TB co-infection, while 23 had miscellaneous diagnoses (figures 1 and 2). ADRs 
were the primary reason for admission in 30.8% (16/52) patients.  There were 61 ADRs for 
these 52 patients, of whom 47 had only 1 ADR, 3 had 2 ADRs and 2 had 4 ADRs each (Table 
3). According to the Naranjo ADR probability scale, the suspected ADRs were classified (table 
5) as possible 61% (31), probable 31% (19) and most probable 8% (5).  
The majority of ADRs in our study were mild 42.6% (26/61) or moderate 45.9% (28/61), while 
only 11.5% (7/61) were severe as shown in table 6. More ADRs were associated with 
chemotherapy 44.3% (27/61) and antimicrobials 42.6% (26/61), while the other miscellaneous 
medicine classes were associated with 34.4% (21/61) of the recorded ADRs. More than half 
55.7% (34/61) of the ADRs were serious, although none was fatal, but 13.1% (8/61) were life 
threatening, 27.9% (17/61) necessitated or prolonged hospitalisation and 14.8% (9/61) resulted 
in persistent or significant disability or incapacity. More than a third 37.7% (23/61) of ADRs 
in our study were type A (dose related). 
Serious ADRs included oncology patients with anaemia (n=2) and febrile neutropaenia (n=3); 
HIV-infected patients with severe diarrhoea (n=1) and rash and vomiting (n=1); TB-infected 
patients with drug induced liver injury (DILI) (n=2) and immune reconstitution inflammatory 
syndrome (IRIS) (n=1); patients with TB-HIV co-infections were also admitted with IRIS 
(n=2); and other diagnoses included acute kidney injury (n=1), ileus (n=1), constipation (n=1) 
and viral meningitis (n=1). 
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Life threatening ADRs included an ampicillin associated anaphylaxis in a 13-month old boy 
admitted for bronchiolitis obliterans. Two TB-infected girls aged 2 and 3 years, respectively, 
were admitted for DILI related to anti-TB treatment. One 7-year old girl with acquired 
immunodeficiency syndrome (AIDS) had aplastic anaemia while on co-trimoxazole 
prophylaxis. Febrile neutropenia after chemotherapy was the reason for admission in 3 patients 
aged 6, 9 and 10 years old respectively. One neonate (27-day old male), was admitted with an 
acute kidney injury with metabolic acidosis and hypoglycaemia associated with the use of a 
topical salicylate preparation (wintergreen ointment) applied to the umbilicus. 
The following were considered disabling or persistent serious ADRs: viral meningitis and 
Cushing’s syndrome attributed to prednisone in a 2-year old child on chronic treatment for 
auto-immune haemolytic anaemia; Cushing’s syndrome in a 10-year old treated for leukaemia; 
3 oncology patients on the combination of doxorubicin, L-Asparaginase, etoposide, carboplatin 
and vincristine for acute lymphoblastic leukemia (ALL) treatment had pancytopaenia and 3 
patients on anti-TB treatment with DILI. 
A higher prevalence 56.5% (13/23) of ADRs occurred in oncology patients on chemotherapy, 
followed by HIV-infected patients on antiretroviral therapy (ART) 42.9% (9/21). HIV-TB co-
infected patients also experienced a high 30.8% (4/13) rate of ADRs. We found that 17.5% 
(7/40) of patients treated for TB had at least one ADR while the miscellaneous group of the 
patients had the lowest prevalence 11.6% (23/198) of ADRs. Oncology patients on 
chemotherapy had a 7-fold increased risk of having an ADR [OR: 7.3 (3.0 – 17.9), p < 0.0001)]. 
Age, sex, HIV status and TB status were not predictive of the possibility of experiencing an 
ADR (table 8).    
 
 




Our findings are consistent with those of larger studies elsewhere(9,18–22), which suggest that 
ADRs are a significant cause of morbidity, perhaps requiring increased pharmacovigilance. 
The high (18.4%) prevalence of ADRs, of which almost a third (31%) were the cause of 
patient hospitalisation, falls within the ranges seen in both low to middle income countries 
(LMIC) and high income countries (HIC) such as Ethiopia(9) in SSA and United Kingdom 
(UK).(18) Eshetie et al(9) reported an ADR rate of 9.2% in an Ethiopian study of 634 
admissions, while a larger study of 6,601 admissions in the UK by Thiesen et al(18) revealed a 
higher prevalence of 17.7%. However, systematic reviews of studies of ADRs in children 
revealed varied rates of ADRs ranging from 0.6% to 16.8%.(2,3) 
In our study, only malignancy was statistically significantly associated with the prevalence of 
ADRs whereas HIV, TB and others were not. HIV-TB co-infection was also surprisingly not 
predictive of ADR occurrence even though nearly a third (31%) of patients with co-infection 
experienced ADRs. This lack of association is likely due to the small study sample size since 
HIV and TB infections are treated with multiple anti-infective medicines that, similar to 
cancer treatment protocols, are also known to be associated with high rates of ADRs.(8,19,20)  
Moreover, polypharmacy as indicated by both HIV and TB treatment, individually, and in co-
infection, is likely predictive of ADRs. We could not assess the effect of polypharmacy (≥5 
medicines) in our study because information on medicines was only collected for the patients 
who experienced suspected ADRs. However, only 11.5% (6/52) of patients who experienced 
ADRs had ≤ 4 medicines prescribed. The majority 88.5% (46/52) of patients who 
experienced ADRs had polypharmacy. 
The majority of the ADRs in our study were associated with chemotherapy and 
antimicrobials, 44.3% (27/61) and 42.6% (26/61), respectively. All the other drug categories, 
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combined, were associated with less ADRs, 34.4% (21/61). This is consistent with findings in 
systematic reviews(2,3) which reported strong associations between antimicrobials, 
polypharmacy and ADRs. Smyth et al found that 17% of studies showed anti-infective agents 
were the therapeutic class most frequently associated with ADRs.(2) Moreover, the treatment 
of childhood malignancies is known to have one of the highest ADR rates due to the 
complications of intensive multi-drug cancer treatment protocols.(14,21)  
Also consistent with the international studies(2,3,6,8,9,14) which assessed a very small proportion 
of suspected ADRs with a high degree of certainty, most (61%) of the suspected ADRs in our 
study could only be assessed as possible ADR while 31% were assessed as probable and only 
a few (8%) were assessed as most probable. Even a large multicentre cohort of 1340 admissions 
conducted by Rashed et al only assessed 7.9% of identified ADRs as definite while the majority 
were assessed as possible 26.8% and probable 65.3%.(6) Equally few (7.3%) ADRs were 
assessed as definite by Thiesen et al.(20) These findings highlight the difficulties of attributing 
adverse clinical outcomes to the treatment rather than to the disease process. This difficulty 
increases when multiple medicines are combined in complex treatment regimens as it becomes 
more difficult to isolate the individual culprit medicine(s). A significant proportion (38%) of 
ADRs in our study were type A (dose related), which means they were predictable. This 
highlights the importance of good pharmacovigilance to help anticipate and mitigate the 
morbidity caused by these ADRs. 
Our study contributes to the limited data and documents the prevalence of ADRs in paediatric 
in-patients in the SSA and South Africa in particular. We believe the strength of our study lies 
in its prospective nature which enables better identification of ADRs than a retrospective study 
would. However, notable limitations include the short duration of three months and the 
resultant small sample size; the study was conducted from a single site. Some ADRs might 
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have been missed and some ADRs such as nausea in inexpressive, under age children may have 
been missed. The study also did not analyse the effect of off-label medication use, as well as 
length of hospital stay on the prevalence of ADRs. The specificity of ADR causality could not 
be established as we could not determine which components of the different treatment regimens 
were responsible for the ADR. We therefore listed all medicines plausibly linked to the 
identified ADR as culprit medicines. A larger sample size with power to investigate more sub-
population comparisons and perhaps inclusion of other relevant potentially predictive variables 
such as off-label medicines should be considered for future studies. 
Conclusion      
The high prevalence (18.4%) of ADRs and the high proportion (38%) of potentially preventable 
ADRs give impetus to institute a concerted and sustained drive towards improved 
pharmacovigilance. These data provide important baseline information that may prove crucial 
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Figure 2: Relationship between ADR and the overlap of HIV-TB co-infection 
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Table 1: Naranjo Adverse Drug Reaction (ADR) Probability Scale(13) 
Questions Yes No Don’t know 
Are there previous conclusive reports on the ADR? +1 0 0 
Did the ADR appear after the medicine was administered? +2 -1 0 
Did the ADR improve when the medicine was 
discontinued? 
+1 0 0 
Did the ADR appear with rechallenge with medicine? +2 -1 0 
Are there alternative causes of the ADR? -1 +2 0 
Did the reaction appear when placebo was given? -1 +1 0 
Was the medicine detected in blood at toxic levels?  +1 0 0 
Was the reaction more severe when the dose was increased 
or less severe when the dose was decreased? 
+1 0 0 
Did the patient have a similar reaction to the same or 
similar medicine in any previous exposure? 
+1 0 0 
Was the ADR confirmed by any objective evidence? +1 0 0 
Each question is rated from -2 to +2. A total score ≥9 points: most probable; 5 to 8: 
probable; 1 to 4: possible and ≤ 0: doubtful 
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Table 2: Hartwig severity scale(14) 
Severity Description  
Mild ADRs which are self-limiting, resolve without treatment and do not 
contribute to prolongation of length of stay. 
Moderate ADRs which require therapeutic intervention and hospitalization prolonged 
by 1 day but resolved in <24 h or change in drug therapy or specific treatment 
to prevent a further outcome. 
Severe ADRs which result in disability, prolonged hospital stay or lead to 
hospitalization, required intensive medical care, life threatening or led to the 
death of the patient. 
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Table 3: Summary of ADRs and implicated drugs 
ADR Description Patients (n) Drug(s) implicated 


















Ferrous sulphate; baclofen; 
tilidine; morphine. 
Tilidine. 






































Oil of wintergreen. 
Prednisone. 

















Febrile neutropaenia   
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ADR: Adverse drug reaction; DILI: Drug induced liver injury; IRIS: Immune reconstitution 
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Table 4: Prevalence of ADRs per disease subgroup 





    
Malignancy 13 23 56.5 
HIV infected 9 21 42.9 
TB infected 7 40 17.5 
Others 23 198 11.6 
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Table 5: ADR causality assessment 
ADR  Naranjo score n   (%) 
Most probable ≥ 9 5    (8) 
Probable 5 - 8 19  (31) 
Possible 1 - 4 37  (61) 
Total  61 (100) 
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Table 6: ADR severity categories 
Severity Proportion   (%) 
Mild 26/61  (42.6) 
Moderate 28/61  (45.9) 
Severe 7/61     (11.5) 
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Table 7: Seriousness assessment 
Seriousness n    (%) 
Fatal 0     (0) 
Life threatening 8     (13) 
Cause/prolong hospitalisation 17   (28) 
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Table 8: Factors associated with ADRs 
 
Factor 
Univariate logistic regression Multivariate logistic regression 
OR 95%CI P-value OR 95%CI P-value 
Age 1.00 0.99 – 1.01 0.48 1.00 0.99 – 1.01 0.97 
Sex (Male) 0.62 0.34 – 1.14 0.12 0.54 0.28 – 1.03 0.06 
HIV status 1.01 0.26 – 3.96 0.18 1.04 0.23 – 4.68 0.96 
TB status 0.93 0.39 – 2.23 0.87 0.80 0.28 – 2.28 0.68 
Oncology status 7.33 3.01 – 17.89 <0.01 8.71 3.39 – 22.37 <0.01 
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Title: Adverse drug reactions in paediatric in-patients in a South African tertiary hospital: A prospective 
observational study. 
Background and rationale 
 
The World Health Organisation defines an adverse drug reaction (ADR) as a response to a medicine that is 
noxious and unintended and occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of 
disease, or for modification of physiological function (1). Notably, this definition is not as inclusive as that of 
adverse events (AEs) which includes all adverse outcomes that occur to patients who take medication without 
regard to the causal relationship between the medication and the adverse outcome concerned. ADRs (a subset 
of AEs) are therefore focused on the harmful outcome in the patient whereas adverse drug events include 
medication errors and intentional overdose which do not necessarily have to result in negative clinical effects 
(1). Medication errors involve mistakes in the medicine administration process which do not necessarily result 
in negative clinical effects. This distinction is very important since health care facilities which fail to recognize 
the difference between medication errors and ADRs may concentrate their efforts on systems that improve 
the accuracy of medicine administration but that produce only marginal reductions in patient harm (2). 
 
The prevalence of ADRs may be higher than generally reported, considering treatment with medicine is the 
most common medical intervention. Rieder and colleagues reported that an average of 4 prescriptions per 
child per annum were written (3), confirming the high frequency of  treatment with medication. However, this 
frequency is much higher in certain populations of children, such as those with chronic diseases and 
malignancies, who tend to use more prescription medication and hence have a higher risk of ADRs (4–7). The 
importance  of ADRs has been highlighted by four  systematic reviews conducted between 1966 and 2012 in 
different therapeutic settings in children, (4,6,8,9). Even though the reported  prevalence of ADRs varies from 
country to country in the developed world, the consistent finding is that the prevalence of ADRs in hospitalised 
paediatric patients (9.5%) is at least comparable to that of  adult patients (10).  ADRs are of significant public 
health and health economic concern since as many as 2% of paediatric patients were admitted as a direct 
result of ADRs, leading to additional hospitalisation days and treatment costs (10). Thirty nine per cent of the 
admissions precipitated by ADRs were due to serious ADRs (6) which often required more specialised care . 
This signifies considerable morbidity and mortality (4) and highlights the importance of investigating the actual 
prevalence of ADRs and causes thereof.  
 
An assessment (11) of the impact of ADRs on patients revealed that the majority, 73%,  of ADRs had a low 
impact on patients (i.e. necessitated minor treatment) while only 2% had a severe impact (i.e. caused 
permanent damage or life threatening to patients). Considering the high prevalence of ADRs, 2% translates to 
significant numbers. Catastrophic ADRs, defined as those that result in death are rare, 0.1%, while those with 
moderate impact (i.e. requiring moderate increase in treatment but causing no permanent harm to the 
patient) occur more commonly, 25%. This assessment also revealed that as much as 55% of ADRs were either 
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definitely or possibly avoidable.  This implies poor management of ADRs in terms of inadequate anticipation 
and prevention which is probably due to inadequate awareness among clinicians.  In countries where the 
prevalence of ADRs is known such as the Netherlands, ADRs were found to increase the average length of 
hospital stay by 6.2 days resulting in average additional cost of €2500 (12) per patient.  
 
Smyth and group highlighted the association between certain therapeutic classes of medicines such as opioids 
and ADRs (8). This finding is also supported by Rashed et al 2012 who correlated the frequent use of high-risk 
medicines such as morphine with the higher incidence of ADRs in the United Kingdom than other European 
countries (10). Paediatric oncology has one of the highest ADR rates due to the complications of intensive 
multidrug treatment protocols of childhood malignancies (3). 
 
Despite the extensive literature in the developed world, including the four systematic reviews discussed above, 
the developing world, including Sub-Saharan Africa lacks data on paediatric ADRs. However, a recent adult 
study  found the prevalence of ADRs in hospitalised adults to be 14% (13). Considering that children are at 
higher risk of ADRs partly because of a significantly higher off-label medicines use than in the adult population 
(14), a higher prevalence of ADRs than 14% is expected in the hospitalised paediatric population of a local 
hospital. The unavailability of local prevalence data on ADRs in the paediatric population limits our 
understanding of factors that influence which patients are more likely to develop ADRs than others. The often 
quoted rates of commonly occurring ADRs are derived from efficacy studies (Yaffe & Aranda, 1992) which are 
frequently poorly representative of the medicine’s target population. Clinical trials for marketing approval are 
sufficiently large (a few hundreds or thousands of subjects) to evaluate efficacy but inadequate for 
characterising the frequency of ADRs. These studies typically exclude relevant patients such as those using 
other medicines than the ones under evaluation. In paediatrics this is further compounded by having fewer 
numbers of study participants per age group, such as premature neonates and adolescents, when studies get 
done at all.  
Spontaneous reporting of ADRs by healthcare workers remains low  (4,6,9,12,15) despite well-established  
reporting means such as the yellow card system. This is despite a significant proportion (15%) of in-patients 
who have ADRs with a considerable proportion  (6.5%) of those admissions having been precipitated by such 
ADRs (7,16). Reasons for the under-reporting of ADRs have been documented (17) as varying from a lack of 
time, competing care priorities, uncertainty about medicine and ADR causal relationship, administrative 
difficulties as well as lack of awareness of the relevance and importance of reporting ADRs (17).  
Data in Sub-Saharan Africa are scanty despite the fact that there are children in this region in various hospitals 
receiving multiple and usually concurrent medicines, some of which are likely associated with ADRs such as 
those typically observed in oncology wards (6,9). There are additional challenges in reporting ADRs in children 
in particular. For instance, young children may be unable to communicate discomfort and therefore depend on 
observant clinicians or caregivers to recognise changes related to the manifestation of the adverse event. The 
resultant low detection might partly explain the low reporting rate of ADRs (9).    
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While the literature shows that ADRs are predominantly related to medication used in chronic diseases of life 
style including cardiovascular, hypoglycaemics and anti-inflammatory drugs, the predominant causes of ADRs 
in adults in a Sub-Saharan African hospital was found to be related to medication directed at the treatment of 
infectious diseases (13). This is probably as a result of the current HIV infection pandemic which fuels 
opportunistic infectious diseases such as tuberculosis, fungal and bacterial infections within this region. It is 
therefore reasonable to expect a difference in the prevalence and nature of ADRs in the paediatric populations 
of Sub-Saharan Africa. 
Approximately a quarter (18) of the world’s burden of HIV associated TB is in South Africa where the estimated 
annual risk of TB infection in children in the Western Cape Province ranges between 4% and 7% (18) per 
annum. TB and HIV co-infection necessitates polypharmacy which which is a risk factor for ADRs (8). However, 
the prevalence of ADRs in this paediatric population is not documented. This knowledge gap needs to be 
closed so as to enable healthcare resource planning and delivery. This study intends to document the 
prevalence, nature and management of paediatric adverse drug events in a tertiary hospital in Cape Town, 
South Africa. 
 
The current clinical management of adverse drug reactions (5) requires that the following steps be followed: 
1. Identification of the possibility of an ADR. 
2. Assessment through a thorough medicine history, timing and rationale thereof, examination and 
exclusion of potential confounders. 
3. Analysis of the differential diagnosis and systematic causality assessment. 
4. Assistance of the patient with relief of symptoms usually by withdrawal of the potential medication 
causing an adverse drug event and instituting appropriate symptomatic and supportive treatment. 
5. Documentation and management of complications when necessary. 
6. Alert the patient, family, other healthcare workers as well as the relevant authorities such as the 
regulatory and pharmacovigilance units. 
This process is both labour intensive and requires significant amounts of time. In order to improve efficiency at 
identifying ADRs, trigger tools which may assist investigators to conduct focused patient chart reviews have 
been used by other researchers (2,19–21). Trigger tools are clues or information in patient records which may 
‘trigger’ further investigation to determine the presence or absence of an adverse drug reaction. In the United 
Kingdom (21) application of the trigger tool reduced patient record review time by an average of more than 
90% while other studies reported significantly more yield of adverse reactions than routine spontaneous 
reporting systems (19,20). Using a trigger tool to identify potential adverse drug reactions therefore appears to 
allow for more efficient patient record reviews and increase the chances of identifying more ADRs than when 
none is used. However, these trigger tools need to be modified and tailored to the specific study environment 
as demonstrated by Rozich et al (2) when they changed the tool to a manual and less expensive one which 
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could be used in hospitals with no electronically integrated patient record systems. The original trigger tools 
were expensive and had limited utility since they required substantial information technology capital and the 
attendant requirement of training (2). Relying on trigger tools to identify ADRs may further limit detection of 
those ADRs associated with, or presenting differently from, the predefined triggers, thereby potentially 
limiting the findings to predefined ADRs.  
Combining the traditional intensive patient chart reviews with a trigger tool might increase the yield and 
identify more adverse drug event than either method alone. However,  due to resource constraints as well as 
limited utility of trigger tools (22,23), this study will utilise the gold standard (22,23), chart reviews, alone.  
Aim 
To describe the prevalence and nature of adverse drug reactions (ADRs) in paediatric inpatients in a South 
African tertiary hospital. 
The primary objective of this study is to: 
1. Determine the prevalence of ADRs 
The secondary objectives are to: 
1. Characterize the nature of the ADRs  
2. Characterize the drugs implicated (causality assessment), including possible predisposing factors for 
ADRs  
3. Compare the prevalence of ADRs in different patient subpopulations such as HIV and/or tuberculosis 




A 3-month prospective observational study of paediatric patients admitted to general paediatric wards will be 
conducted. All paediatric in-patients, aged under 18 years, admitted in those wards at Tygerberg hospital for at 
least 24 hours during the 3-month period will be included. 
This study will use a comprehensive and intensive chart review, the gold standard in pharmacoepidemiology 
(22,23), in order to minimise missing any frequently occurring ADRs. The lead investigator will screen all 
patient records on alternate days of the week to identify any harmful clinical and laboratory patient outcomes 
during admission. All suspected ADRs will be discussed weekly with the two senior supervisors (a clinical 
pharmacologist and a paediatrician). The patient records and laboratory results (where available and 
appropriate) of the patient(s) with suspected ADRs will be assessed to determine by consensus whether the 
observed harmful outcome is an ADR. For those adverse events deemed to be ADRs, a simple validated 
causality assessment tool, the Naranjo probability scale (26) will be applied to assess causality. Due to its 
simplicity, the Naranjo scale is the most widely used causality assessment method (26) since its introduction in 
1981. This scale answers 10 questions which are scored and used to categorise the probability of ADR 
causation into most probable, probable, possible and doubtful as follows: 
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Table 1: Naranjo Adverse Drug Reaction (ADR) Probability Scale 
Questions Yes No Don’t 
know 
Are there previous conclusive reports on the ADR? +1 0 0 
Did the ADR appear before the medicine was administered? +2 -1 0 
Did the ADR improve when the medicine was discontinued? +1 0 0 
Did the ADR appear with rechallenge with medicine? +2 -1 0 
Are there alternative causes of the ADR? -1 +2 0 
Did the reaction appear when placebo was given? +1 +1 0 
Was the medicine detected in blood at toxic levels?  +1 0 0 
Was the reaction more severe when the dose was increased or less severe when 
the dose was decreased? 
+1 0 0 
Did the patient have a similar reaction to the same or similar medicine in any 
previous exposure? 
+1 0 0 
Was the ADR confirmed by any objective evidence? +1 0 0 
Each question is rated from -2  to +2. A total score ≥9 points: most probable; 5 to 8: probable; 1 to 4: possible 
and ≤ 0: doubtful 
 
The Hartwig severity scale (table 2) will be used to classify ADR severity in terms of being mild, moderate or 
severe (25) while the seriousness of the ADR will be assessed in accordance with the International Conference 
on Harmonisation (ICH) and Council for International Organizations of Medical Sciences (CIOMS) definitions 
(26) based on patient’s outcome. Seriousness will therefore be categorised on the basis of whether the patient 
outcome is “fatal, life threatening, necessitates hospitalisation, prolongs existing hospitalisation or results in 
persistent or significant disability or incapacity”(26). 
Table 2: Hartwig severity scale 
Severity Description 
Mild ADRs which are self-limiting, resolve without treatment and do not contribute to prolongation 
of length of stay. 
Moderate ADRs which require therapeutic intervention and hospitalization prolonged by 1 day but 
resolved in <24 h or change in drug therapy or specific treatment to prevent a further outcome. 
Severe ADRs which result in disability, prolonged hospital stay or lead to hospitalization, required 
intensive medical care, life threatening or led to the death of the patient. 
 
Tygerberg hospital uses a paper-based health record and drug chart system which incorporates an electronic 
system for laboratory results.  
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Once an eligible patient completes 24 hours of hospital admission, the lead investigator will review their 
hospital records to screen for clinical and laboratory indication of the possibility of an ADR (documented as: 
definite/probable/possible). If present, grading, causality and preventability assessments will be done.  
The study will therefore collect data from all eligible in-patient records necessary for determining whether or 
not an ADR exists in a participant, determining the characteristics of such ADRs including grading, causality and 
preventability as detailed in Annexure 1 (Excel workbook: ADR Study Data Collection Tool 2015).  
During hospital stay, patients will repeatedly be screened and assessed for the development of ADRs on 
alternate days. The clinicians in charge of patients in the chosen wards will also alert the lead investigator to 
investigate when ADRs are suspected. Upon discharge, inpatient records will again be reviewed (when 
necessary, i.e. confirm or exclude ADR) to document presence or absence of ADR. 
Ethical considerations 
All admissions to the selected paediatric wards will be included in the study. As this is an observational study 
which will not assign any intervention to the study participants or even alter their current standard of care, the 
study participants are not likely to be harmed by the study. Ethics approval and a waiver of informed consent 
will be sought from the Stellenbosch Health Research Ethics Committee before the study commences. 
Confidentiality will be strictly maintained at the data analysis and reporting level by using unique patient 
identification numbers rather than patient identification data such as name, national identification number or 
hospital folder number. 
All identified adverse drug reactions will be reported to the treating clinicians who will be encouraged to 
inform the patients or their caregivers while managing the adverse drug reactions as per their standard 
protocol. 
Envisaged outputs of this study, which will be conducted in accordance with the 2013 Declaration of Helsinki, 
the South African Department of Health’s 2004 Guidelines as well as the South African Good Clinical Practice 
(SA-GCP) Guidelines are: 
1. Publication 
2. Conference presentations 
3. Masters of Medicine (MMed) degree project 
Permission for access to medical records for the purposes of the study will also be sought from the Chief 
Executive Officer of Tygerberg Hospital prior to the commencement of the study. 
Sample size calculation 
Considering the proportion of ADRs reported in adult inpatients in a South African study  (13) of 14% and the 
expectation of a higher adverse drug reaction in children based on the higher prevalence of off-label drug use, 
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we liberally increased the expected proportion to 21% (i.e. a 50% increase on the reported adult prevalence). 
According to the simplified sample size calculation for a population of undefined size (15), using an accepted 
margin of error α = 0.05, a 95% confidence interval and power of 90%, the sample size required to determine 
the prevalence of ADRs in paediatric inpatients of Tygerberg hospital would  be 255 patients.     
Based on the Tygerberg hospital’s wards G3 and G10 current combined admissions averaging 110 patients per 
month, a larger sample which would improve our power for analyses pertinent to secondary objectives is 
obtainable in the allocated 3 months. 
Statistical analysis 
Data will be entered on an Excel spread sheet and all patients who complete the study will be included in the 
analysis. Total days of admission will be documented and prescription episodes will be used to compute the 
rates of ADRs and their different characteristics of interest such as seriousness and preventability. Categorical 
data will be expressed as proportions (%), and continuous data as means with standard deviations (SD). 
Nonparametric data will be summarized using medians and interquartile ranges (IQR) and compared using the 
Kruskal–Wallis test. Comparisons with the local data on adult ADRs as well as and the international data on in-
patient paediatric ADRs will be discussed.  
Table 3: Study timeline 
Activity Year 2015 Year 2016 





            
Data 
collection 





            
Submission 
to faculty 
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Title: Adverse drug reactions in paediatric in-patients in a South African tertiary hospital: A prospective 
observational study. 
MMed Clinical Pharmacology Candidate: Memela M. Makiwane. 
Supervisors: Dr EH Decloedt, Prof B Rosenkranz & Prof M Kruger. 
Aim and objectives 
 
To describe the prevalence and nature of adverse drug reactions (ADRs) in paediatric in-patients in a South 
African tertiary hospital. 
The objectives of this study are to: 
1. Determine the prevalence of ADRs. 
2. Characterize the nature of the ADRs.  
3. Characterize the drugs implicated (causality assessment), including possible predisposing factors for 
ADRs.  
4. Compare the prevalence of ADRs in different patient subpopulations such as HIV and/or tuberculosis 
infected and oncology patients. 
 
Background and rationale 
Despite the extensive literature in the developed world, the developing world, including Sub-Saharan Africa 
lacks data on paediatric ADRs. The unavailability of local prevalence data on ADRs in paediatrics limits our 
understanding of determinants of ADRs which negatively impacts their management.  ADRs are of significant 
public health and health economics concern since as many as 2% of paediatric patients were admitted as a 
direct result of an ADRs, leading to additional hospitalisation days and treatment costs (Rashed et al. 2012). 
Thirty nine per cent of the admissions precipitated by ADRs were due to serious ADRs (Impicciatore et al. 2001) 
which often required more specialised care . This signifies considerable morbidity and mortality (Aagaard et al. 
2010) and highlights the importance of investigating the actual local prevalence of ADRs and causes thereof.  
 
Study design 
A 3-month prospective observational study of paediatric patients aged under 18 years, admitted to Tygerberg 
hospital paediatric wards G3 and G10 for at least 24 hours, within the study period, will be conducted. 
Comprehensive and intensive chart reviews will be undertaken on alternate days of the week by the lead 
investigator who will screen all patient records in participating wards to identify harmful clinical and laboratory 
patient outcomes at and during admission. Identified ADRs will be graded for severity.  Causality, 
preventability and seriousness assessments will be done. 
Ethics 
A waver of informed consent will be requested from the University of Stellenbosch Research Ethics 
Committee. De-identified data analysis will be performed.  Identified ADRs will be reported to treating 
clinicians for appropriate management. 
 
Anticipated outcomes and significance 
Documentation of the prevalence and determinants of ADRs in paediatric in-patients in South Africa. 
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Purpose: This procedure provides instruction on the step by step conduct of the study. 
Procedure: 
1. Consenting:  
1.1. The Principal Investigator administers the consent and assent to the parent and the 
minor participant, respectively, on admission. 
1.2. All paediatric admissions, aged under 18 years, admitted in the participating wards are 
to be invited to participate in the study. 
2. Comprehensive and intensive chart review:  
2.1. Once a consented patient completes 24 hours of hospital admission, the lead 
investigator will review their hospital records to screen for clinical and laboratory 
indication of the possibility of an ADR. 
2.2. The Naranjo Adverse Drug Reaction (ADR) Probability Scale will be used to determine 
probability and present as definite/probable/possible).  
2.3. Assess whether the reason (diagnosis) for admission is an ADR 
2.4. Assess whether the patient has experienced or is experiencing an ADR during 
admission. 
2.5. If ADR is detected, grading, causality and preventability assessments will be done as 
follows: 
2.6. The Hartwig severity scale will be used to classify ADR severity in terms of being mild, 
moderate or severe.  
2.7. Seriousness of the ADR will be assessed in accordance with the International 
Conference on Harmonisation (ICH) and Council for International Organizations of 
Medical Sciences (CIOMS) definitions based on patient’s outcome as “fatal, life 
threatening, necessitates hospitalisation, prolongs existing hospitalisation or results 
in persistent or significant disability or incapacity 
2.8. The Hartwig severity scale will be used to classify ADR severity in terms of being mild, 
moderate or severe.  
2.9. Clinicians in charge of patients in the chosen wards will also alert the lead investigator 
to investigate when ADRs are suspected. 
2.10. Principal Investigator will present weekly findings to at least one supervisor at a 
meeting to discuss and agree (by consensus) on the classification, grading, causality 
and preventability assessments of the detected ADRs. 
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2.11. Upon discharge, inpatient records will again be reviewed (when necessary, i.e. confirm 
or exclude ADR) to document presence or absence of ADR. 
3. Documentation: 
3.1. Data will be documented on an excel spread sheet – Protocol Annexure 1  
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Annexure 2: Parent/guardian/caregiver Information leaflet and Informed Consent Form 
 
Title: Adverse drug reactions in paediatric in-patients in a South African tertiary hospital: A prospective 
observational study. 
 
Reference number: S15/08/171. 
 
Study Doctor: Dr Memela M Makiwane MB.ChB (UCT), Dip HIV Man (SA), PGDip Pharm Med (Stell). 
 
Address: 7060 Clinical Building, Faculty of Medicine and Health Sciences, Stellenbosch University.  
 
Contact number: 021 938 9335 
 
Introduction: You are being asked to take part in this research study because we want to determine 
how often adverse drug reactions (ADRs) happen to children admitted to Tygerberg Hospital. We also 
want to determine if your child has suffered an adverse drug reaction and, if so, how ill this made 
your child.  An adverse drug reaction is any unwanted, uncomfortable, or dangerous effect that a 
patient may suffer from after taking a medicine (drug). For example, a patient with an infection may 
have an adverse drug reaction such as a rash after receiving an antibiotic. 
 
This study has been approved by the Health Research Ethics Committee at Stellenbosch University and 
will be conducted according to the ethical guidelines and principles of the international Declaration of 
Helsinki, South African Guidelines for Good Clinical Practice and the Medical Research Council (MRC) 
Ethical Guidelines for Research. 
 
What is this research study all about? 
We want to know how often adverse drug reactions (ADRs) occur in children admitted to Tygerberg 
Hospital. We also want to know if your child has suffered an adverse drug reaction and, if so, how ill 
this made your child. We also want to know what causes these adverse drug reactions. 
 
Why have you been invited to participate? 
We are inviting all children who need to be admitted to selected children’s wards of Tygerberg Hospital 
during the study period to take part in the study.   
 
What will your responsibilities be? 
The study doctor will check your child’s hospital records and  results of his/her tests to see if s/he got ill 
because of an adverse drug reaction, got an adverse drug reaction while in hospital or not. You will not 
be required to do any activity for the study. 
 
Will you benefit from taking part in this research? 
The study doctor will inform you whether your child has suffered an adverse drug reaction, if that is so, 
and why that has happened.  
 
Are there any risks involved in your taking part in this research? 
There are no risks for you or your child. This research is only looking at what normally happens to 
children on treatment in hospitals. 
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If you do not agree to take part, what alternatives do you have? 
You are free to refuse taking part in the study and your child will still receive the same treatment 
required for the illness for which s/he is admitted.  
 
Who will have access to your medical records? 
Only the doctors treating your child and the study doctor will know s/he is in the study. When the 
research is finished, other doctors will be told about what was found but no one else will know that your 
child was in the study. That is because no one’s name will be included when telling other doctors about 
what was found by the research. 
What will happen in the unlikely event of some form of injury occurring as a direct result of your 
taking part in this research study? 
It is very unlikely that any injury could result from taking part in the study since the study only observes 
what normally happens to children admitted and treated in hospital. 
 
Will you be paid to take part in this study and are there any costs involved? 
 
No, your child and you will not be paid to take part in the study.  
 
Is there anything else that you should know or do? 
You can contact the Health Research Ethics Committee at 021 938 9207 if you have any concerns or 
complaints that have not been adequately addressed by your study doctor. 
Declaration by parent/guardian/caregiver: 
 
By signing below, I …….…………………………………..……………………………...agree for my dependent to take part 
in this research study. 
 
I declare that: 
 
 I have read or had read to me this information and consent form and it is written in a 
language I understand.   
 I have had a chance to ask questions and all my questions have been adequately answered. 
 I understand that taking part in this study is voluntary and I have not been pressurised to 
take part. 
 I may choose to leave the study at any time and will not be penalised or prejudiced in any 
way. 
 




 ............................................................................ …..  
Signature of parent/guardian/caregiver  
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Declaration by investigator 
 
I (name) ………………………………………………………..…………………………………………..……………….. declare that: 
 
 I explained the information in this document to …………………………………………………………………. 
 I encouraged him/her to ask questions and took adequate time to answer them. 








 ............................................................................   .......................................................................... 
Signature of investigator Signature of witness 
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Bylaag 2: Inligtingsblaadjie en oorwoëtoestemmingsvorm vir ouer/voog/versorger 
 
Titel: Nadelige middelreaksies by pediatriese hospitaalpasiënte in ŉ Suid-Afrikaanse tersiêre hospitaal: 




Studiedokter: Dr. Memela M Makiwane MB,ChB (UK), Dip MIV/Vigs-best (SA), NGDip Farm Gen (Stell) 
 
Adres: Kliniese Gebou 7060, Fakulteit Geneeskunde en Gesondheidswetenskappe, Universiteit 
Stellenbosch  
 
Kontaknommer: 021 938 9335 
 
Inleiding: Jy word gevra om aan hierdie navorsingstudie deel te neem omdat ons wil bepaal hoe dikwels 
nadelige middelreaksies plaasvind by kinders wat in Tygerberg-hospitaal opgeneem word. Ons wil ook 
bepaal of jou kind ŉ nadelige middelreaksie ervaar het en, indien wel, hoe siek dit jou kind gemaak het. 
ŉ Nadelige middelreaksie is enige ongewenste, ongerieflike of gevaarlike effek wat ŉ pasiënt kan ervaar 
nadat ŉ middel (medikasie) geneem is. ŉ Persoon met ŉ infeksie kan byvoorbeeld ŉ nadelige 
middelreaksie, soos ŉ uitslag, ondervind nadat ŉ antibiotikum toegedien is. 
 
Die studie is deur die Gesondheidsnavorsingsetiekkomitee van die Universiteit Stellenbosch 
goedgekeur en sal uitgevoer word in ooreenstemming met die etiekriglyne en -beginsels van die 
internasionale Verklaring van Helsinki, Suid-Afrikaanse riglyne vir goeie kliniese praktyk en die Mediese 
Navorsingsraad se etiekriglyne vir navorsing. 
 
Waaroor gaan hierdie navorsingstudie? 
Ons wil weet hoe gereeld nadelige middelreaksies plaasvind by kinders wat in Tygerberg-hospitaal 
opgeneem word. Ons wil ook bepaal of jou kind ŉ nadelige middelreaksie ervaar het en, indien wel, hoe 
siek dit jou kind gemaak het. Ons wil ook weet wat hierdie nadelige middelreaksies veroorsaak. 
 
Hoekom is jy genooi om deel te neem? 
Ons nooi alle kinders wat by gekose kindersale van Tygerberg-hospitaal tydens die studietydperk 
opgeneem moet word om aan die studie deel te neem. 
 
Wat sal jou verantwoordelikhede wees? 
Die studiedokter sal jou kind se hospitaalrekords en uitslae van sy/haar toetse nagaan om te bepaal of 
hy/sy siek geword het as gevolg van ŉ nadelige middelreaksie en of jy ŉ nadelige middelreaksie ervaar 
het terwyl jy in die hospitaal was. Daar sal nie van jou verwag word om enige aktiwiteit vir die studie 
uit te voer nie. 
 
Sal jy voordeel trek uit deelname aan hierdie navorsing? 
Die studiedokter sal jou in kennis stel as jou kind ŉ nadelige middelreaksie ervaar het, en indien wel, 
waarom dit gebeur het.  
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Is daar enige risiko’s verbonde aan jou deelname aan hierdie navorsing? 
Daar is geen risiko’s vir jou of jou kind nie. Hierdie navorsing behels bloot ŉ ondersoek na wat gewoonlik 
met kinders gebeur met behandeling in hospitale. 
 
Wat sal gebeur as jy nie instem om deel te neem nie? 
Jy kan weier om aan die studie deel te neem, en jou kind sal steeds dieselfde behandeling ontvang wat 
nodig is vir die siekte waarvoor hy/sy opgeneem is.  
 
Sal enige iemand toegang tot jou kind se mediese rekords hê? 
Net die dokters wat jou kind behandel en die studiedokter sal weet dat hy/sy aan die studie deelneem. 
Wanneer die navorsing voltooi is, sal ons ander dokters inlig oor wat ons bevind het, maar hulle sal nie 
weet dat jou kind aan die studie deelgeneem het nie. Dit is omdat niemand se naam gebruik sal word 
wanneer ons ander dokters van die bevindinge van die navorsing vertel nie. 
Wat sal gebeur in die onwaarskynlike geval dat ŉ vorm van besering voorkom as ŉ direkte gevolg van 
deelname aan hierdie navorsingstudie? 
Dit is hoogs onwaarskynlik dat enige besering sal plaasvind as gevolg van deelname aan die studie, 
aangesien die studie slegs waarneming behels van wat normaalweg met kinders gebeur wat in ŉ 
hospitaal opgeneem en behandel word. 
 
Sal jy betaal word om aan die studie deel te neem en is daar enige koste daarby betrokke? 
 
Nee, jy en jou kind sal nie betaal word om aan die studie deel te neem nie en dit sal jou ook niks kos nie.  
 
Is daar enigiets anders wat jy moet weet of doen? 
Jy kan die Gesondheidsnavorsingsetiekkomitee skakel by 021 938 9207 as jy enige bekommernisse of 
klagtes het wat nie voldoende deur jou studiedokter hanteer is nie. 
 
Verklaring deur ouer/voog/versorger: 
 
Deur hier onder te onderteken, stem ek, …….…………………………………..…………………………….., in dat my 
afhanklike aan hierdie navorsingstudie mag deelneem. 
 
Ek verklaar dat: 
 
 Ek hierdie inligting en toestemmingsvorm gelees het of dat dit vir my voorgelees is en dat 
dit geskryf is in ŉ taal wat ek verstaan. 
 Ek kans gekry het om vrae te vra en dat al my vrae bevredigend beantwoord is. 
 Ek verstaan dat my deelname aan hierdie studie vrywillig is en dat ek nie onder druk 
geplaas is om deel te neem nie. 
 Ek verstaan dat ek kan besluit om die studie op enige tyd te verlaat en dat ek op geen 
manier gepenaliseer of benadeel sal word nie. 
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 ............................................................................ …..  
Handtekening van ouer/voog/versorger  
Verklaring deur ondersoeker / dokter 
 
Ek (naam), ………………………………………………………..…………………………………………..……………….., verklaar dat: 
 
 Ek die inligting in hierdie dokumente aan ………………………………….. verduidelik het. 
 Ek hom/haar aangemoedig het om vrae te vra en genoeg tyd gebruik het om dit te 
beantwoord. 








 ............................................................................   .......................................................................... 
Verklaring deur ondersoeker / dokter Handtekening van getuie  
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Iingxaki zokungamelani namachiza kubantwana abazizigulane ezilaliswe kwisibedlele esikumgangatho ophezulu eMzantsi 
Afrika: Uphononongo oluqwalasela okunokwenzeka.  
Isihlomelo sesi-2: Iphetshana elineeNkcukacha zoMzali / zomgcini womntwana / zomnonopheli neFomu 
yesiVumelwano. 
 
Isihloko: Iingxaki zokungamelani namachiza kubantwana abazizigulane ezilaliswe kwisibhedlele 
esikumgangatho ophezulu eMzantsi Afrika: Uphononongo oluqwalasela okunokwenzeka.  
 
Inombolo yesalathisi: S15/08/171. 
 
Ugqirha woPhononongo: uGqr. Memela M Makiwane MB.ChB (UCT), Dip HIV Man (SA), PGDip Pharm 
Med (Stell). 
 
Idilesi: 7060 Clinical Building, Icandelo leNzululwazi ngezaMayeza nezeMpilo, kwiYunivesithi 
yaseStellenbosch.  
 
Inombolo yoqhagamshelwano: 021 938 9335 
 
Intshayelelo: Uyacelwa ukuba uthathe inxaxheba kolu phononongo lophando kuba sifuna ukufumanisa 
iingxaki zokungamelani namachiza (ADRs) kubantwana abalaliswa kwiSibhedlele saseTygerberg. Sifuna 
nokufumanisa ukuba ingaba umntwana wakho ukhe wanengxaki yokungamelani namachiza kwaye, ukuba 
kunjalo, kumenze wagula njani umntwana wakho. Iingxaki zokungamelani namachiza zizo naziphi na 
iimpembelelo ezingafunekiyo, zokwenza ungakhululeki okanye ubesengozini xa usebenzise amayeza 
(ichiza). Umzekelo, isigulane esiye sosuleleka singanayo ingxaki yokungamelani namachiza nto leyo efana 
nerhashalala emva kokusebenzisa amayeza alwa ukosuleleka yintsholongwane. 
 
Olu phononongo luvunywe yiKomiti ejongene nokuziPhatha kuPhando lwezeMpilo kwiYunivesithi 
yaseStellenbosch kwaye luza kwenziwa ngokwemigaqo nemithetho-siseko yeSibhengezo sikazwelonke 
saseHelsinki, iMigaqo yaseMzantsi Afrika kwiZenzo eziLungileyo kwezeMpilo neMigaqo yokuziPhatha 
kweBhunga loPhando kwezeMpilo (MRC). 
 
Lumalunga nantoni olu phononongo? 
Sifuna ukwazi ukuba zibakho kangakanani na iingxaki zokungamelani namachiza (i-ADR) kubantwana 
abalaliswe kwiSibhedlele saseTygerberg. Sifuna nokwazi ukuba ingaba umntwana wakho ebekhe wanayo na 
ingxaki yokungamelani namachiza kwaye, ukuba kunjalo, kumenze wagula njani umntwana wakho. Sifuna 
nokwazi ukuba yintoni eyenze le ngxaki yokungamelani namachiza. 
 
Kutheni umenyiwe ukuba uthathe inxaxheba? 
Simeme bonke abantwana abazakulaliswa kumawadi abantwana akhethiweyo kwiSibhedlele 
saseTygerberg ngexesha kusenziwa uphononongo ukuba bathathe inxaxheba kolu phononongo.   
 
Luza kuba yintoni uxanduva lwakho? 
Ugqirha owenza uphononongo uza kujonga iingxelo zomntwana zasesibhedlele neziphumo zovavanyo 
lwakhe ukujonga ukuba uguliswe kuba enengxaki yokungamelani namachiza, ubenengxaki 
yokungamelani namachiza ngeli xesha asesibhedlele okanye engekho sesibhedlele. Akukho nto kuza 
kufuneka uyenze kolu phononongo. 
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Ingaba uza kuxhamla ngokuthatha kwakho inxaxheba kolu phando? 
Ugqirha owenza uphononongo uza kukwazisa ukuba umntwana wakho unengxaki yokungamelani 
namachiza, ukuba kunjalo, yintoni eyenze oko.  
 
Ingaba bukhona ubungozi obubandakanyekayo xa uthatha inxaxheba kolu phando? 
Akukho bungozi obuza kubakho kuwe okanye kumntwana wakho. Olu phando lujonga ukuba yintoni 
eqhelekileyo eyenzekayo kubantwana abafumana unyango kwizibhedlele. 
 
Ukuba awufuni kuthatha inxaxheba, zeziphi ezinye izinto ezinokwenziwa? 
Ukhululekile ukuba ungala ukuthatha inxaxheba kuphononongo kwaye umntwana wakho uhleli eza 
kulufumana unyango olufunekayo kwisigulo anaso alaliselwe sona  
 
Ngubani oza kuzifumana iingxelo zakho zonyango? 
Ngoogqirha kuphela abanyanga umntwana wakho nogqirha owenza uphononongo abaza kumazi ukuba 
ukolu phononongo. Xa lugqityiwe uphando, abanye oogqirha baza kuxelelwa oko kufunyanisiweyo 
kodwa akukho namnye oza kumazi ukuba umntwana wakho ebekolu phononongo. Oku kwenzeka kuba 
akukho gama lamntu lifakwayo xa kuchazelwa abanye oogqirha oko kuye kwafunyaniswa luphando. 
Kuza kwenzeka ntoni xa kunokubakho umenzakalo owenzeke ngenxa yokuthatha kwakho inxaxheba 
kolu phando? 
Akufane kwenzeke ukuba umntu afumane nawuphi na umenzakalo obangelwa kukuthatha kwakho 
inxaxheba njengoko uphononongo luqwalasela nje kuphela oko kuqhele ukwenzeka kubantwana 
abalaliswe esibhedlele. 
 
Ingaba uza kuhlawulwa na ngokuthatha kwakho inxaxheba kolu phononongo kwaye ingaba zikhona 
na iindleko ezibandakanyekayo? 
 
Hayi, wena nomntwana wakho anizi kuhlawulwa ngokuthatha kwenu inxaxheba kolu phononongo.  
 
Ingaba ikhona na enye into ekufuneka uyazi okanye uyenze? 
Ungaqhagamshelana neKomiti ejongene nokuziPhatha kuPhando lwezeMpilo ku-021 938 9207 ukuba 
kukho nantoni na ekuxhalabisayo okanye nasiphi na isikhalazo esingaqwalaselwanga ngokwaneleyo 
ngugqirha wakho wophononongo. 
 
Isibhengezo somzali/somgcini womntwana/somnonopheli: 
 
Ngokutyikitya ngezantsi, mna …….…………………………………..……………………………... ndiyavuma ukuba lowo 




 Ndizifundile okanye ndizifundelwe ezi nkcukacha nale fomu yesivumelwano kwaye zibhalwe 
ngolwimi endilwaziyo.   
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 Ndibe nalo ithuba lokubuza imibuzo kwaye yonke imibuzo yam iphendulwe 
ngokwanelisayo. 
 Ndiyakuqonda ukuba ukuthatha kwam inxaxheba kolu phononongo oko ndikwenza 
ngokuzithandela kwaye andifakwanga xinezelelo lokuba ndithathe inxaxheba. 
 Ndingakhetha ukuluyeka uphononongo nanini na kwaye andizi kohlwaywa okanye 
ndigwetywe nangayiphi na indlela. 
 




 ............................................................................ …………………… 
Ukutyikitya komzali/komgcini womntwana/komnonopheli  
 
Isibhengezo somphandi / sogqirha omlalisayo 
 
Mna (igama) ………………………………………………………..…………………………………………..……………….ndazisa ukuba: 
 
 Ndizicacisile iinkcukacha ezikolu xwebhu ku…………………………………………………………………………. 
 Ndimkhuthazile ukuba abuze imibuzo kwaye ndathatha ixesha elaneleyo ukuyiphendula. 








 ............................................................................   .......................................................................... 
Ukutyikitya komphandi/kogqirha omlalisayo Ukutyikitya kwengqina 
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Annexure 3: Participant Information Leaflet and Assent Form 
 
 
   
 
Adverse drug reactions in paediatric in-patients in a South African tertiary hospital: A 
prospective observational study. 
 
Researcher: Dr Memela M. Makiwane MB.ChB (UCT), Dip HIV Man (SA), PGDip Pharm Med (Stell) 
What is RESEARCH? 
 
Research is something we do to find new knowledge about the way things (and people) work.  We 
use research projects or studies to help us find out more about disease or illness. Research also 
helps us to find better ways of helping, or treating children who are sick. 
What is this research research all about? 
 
We want to see how often adverse drug reactions (ADRs) happen to children admitted to 
Tygerberg Hospital. We also want to see if you have had an adverse drug reaction and how ill 
that made you. An adverse drug reaction is any unwanted, uncomfortable, or dangerous effect 
that may happen to someone after taking a medicine (drug). For example, someone may get a 
rash after taking medicine. 
 
Who is doing the research? 
 
Dr Memela Makiwane of Tygerberg hospital and Stellenbosch University. 
 
What will happen to me in this study? 
If you agree to be in the study, Dr Makiwane will check your hospital records and  results of your 
tests to see if you got ill because of an adverse drug reaction, got an adverse drug reaction while in 
hospital or not. If Dr Makiwane finds an adverse drug reaction he will tell the doctor(s) who are 
treating you. You will be part of the study until you leave the hospital to go home unless you 
change your mind and choose to stop being in the study while you are still in hospital. 
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Can anything bad happen to me? 
No. This research is only looking at what normally happens to children on treatment in hospitals.  
Can anything good happen to me? 
Yes. You will be told if you had an adverse drug reaction or not.  
Will anyone know I am in the study? 
Only the doctors treating you and the study doctor will know you are in the study. When the 
research is finished, other doctors will be told about what was found but no one else will know 
that you were in the study. That is because no one’s name will be included when telling other 
doctors about what was found in the research. 
 
Who can I talk to about the study?.  
Dr Memela Makiwane 
Phone: 0219389335 
Email: Makiwane@sun.ac.za 
What if I do not want to do this? 
You can say you do not want to be in the study and no one can force 
you to be. Even if you say yes today, you can still change your mind 
and stop being in the study any time just by saying so. That will not get 
you into any trouble. It will also not make anyone change the way you 
are being treated in hospital. 
Do you understand this research study and are you willing to be in it?   
YES  NO 
 
Do you understand that you can pull out of the study at any time? 
YES  NO 
 
 
___________________________    ________________________ 
Name and/or Signature of Child    Date 
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Nadelige middelreaksies by pediatriese hospitaalpasiënte in ŉ Suid-Afrikaanse tersiêre 
hospitaal: ŉ Voornemende waarnemingstudie 
 
Navorser: Dr. Memela M Makiwane MB,ChB (UK), Dip MIV/Vigs-best (SA), NGDip Farm Gen (Stell) 
Wat is NAVORSING? 
 
Navorsing is iets wat ons doen om nuwe kennis te kry van hoe dinge (en mense) werk. Ons gebruik 
navorsingsprojekte of -studies om ons te help om meer oor siektes uit te vind. Navorsing help ons 
ook om beter maniere te vind om siek kinders te help of te behandel. 
Waaroor gaan hierdie navorsing? 
 
Ons wil sien hoe dikwels nadelige middelreaksies plaasvind by kinders wat by Tygerberg-hospitaal 
opgeneem word. Ons wil ook sien of jy ŉ nadelige middelreaksie gehad het en hoe siek dit jou 
gemaak het. ŉ Nadelige middelreaksie is enige ongewenste, ongerieflike of gevaarlike effek wat 
iemand kan ervaar nadat ŉ middel (medikasie) geneem is. Iemand kan byvoorbeeld ŉ uitslag kry 
nadat hy of sy medisyne gedrink het. 
 
Wie doen die navorsing? 
 
Dr. Memela Makiwane van Tygerberg Hospitaal en die Universiteit Stellenbosch. 
 
Wat sal met my gebeur in die studie? 
As jy instem om aan die studie deel te neem, sal dr. Makiwane na jou hospitaalrekords en die uitslae 
van jou toetse kyk om te sien of jy siek geword het van ŉ nadelige middelreaksie of ŉ nadelige 
middelreaksie gehad het terwyl jy in die hospitaal was. As dr. Makiwane ŉ nadelige middelreaksie vind, 
sal hy die dokter of dokters wat jou behandel, daarvan vertel. Jy sal deel wees van die studie totdat jy 
die hospitaal verlaat of huis toe te gaan, of tensy jy van plan verander en nie meer aan die studie wil 
deelneem terwyl jy nog in die hospitaal is nie. 
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Kan enigiets sleg met my gebeur? 
Nee. In hierdie navorsing kyk ons net wat gewoonlik met kinders gebeur wanneer hulle in 
hospitale behandel word.  
Kan enigiets goed met my gebeur? 
Ja. Ons sal vir jou sê of jy ŉ nadelige middelreaksie gehad het of nie.  
Sal enigiemand weet ek neem aan die studie deel? 
Net die dokters wat jou behandel en die studiedokter sal weet dat jy aan die studie deelneem. 
Wanneer die navorsing voltooi is, sal ons ander dokters vertel wat ons gevind het, maar hulle sal 
nie weet dat jy aan die studie deelgeneem het nie. Dit is omdat niemand se naam gebruik sal word 
wanneer ons ander dokters vertel wat ons in die studie gevind het nie. 
 
Met wie kan ek oor die studie praat?  
Dr. Memela Makiwane 
Telefoon: 021 938 9335 
E-pos: Makiwane@sun.ac.za 
Sê nou ek wil nie deelneem nie? 
Jy kan sê jy wil nie aan die studie deelneem nie, en niemand kan jou 
dwing om deel te neem nie. Selfs al sê jy vandag ja, kan jy steeds van 
plan verander en enige tyd vir ons sê as jy nie meer daaraan wil 
deelneem nie. Jy sal glad nie in die moeilikheid kom nie. Dit sal ook nie 
die manier waarop jy in die hospitaal behandel word, verander nie. 
Verstaan jy hierdie navorsingstudie en is jy bereid om daaraan deel te neem?   
JA  NEE 
 
Verstaan jy dat jy enige tyd kan ophou om aan die studie deel te neem? 
JA  NEE 
 
_____________________________    ________________________ 
Naam en/of handtekening van kind    Datum 
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Isihlomelo sesi-3: Iphetshana elineenkcukacha lalowo uthatha inxaxheba neFomu yesiVumelwano 
 
 
   
Iingxaki zokungamelani namachiza kubantwana abazizigulane ezilaliswe kwisibhedlele 
esikumgangatho ophezulu eMzantsi Afrika: Uphononongo oluqwalasela okunokwenzeka. 
 




Uphando yinto esiyenzayo ukufumana ulwazi olutsha malunga nendlela izinto (nabantu) 
abasebenza ngayo. Sisebenzisa iiprojekthi zophando okanye uphononongo ukusinceda sazi 
ngakumbi ngezifo okanye ngezigulo. Uphando lukwasinceda sifumane iindlela ezingcono 
zokunceda okanye zokunyanga abantwana abagulayo.  
Lumalunga nantoni olu phando? 
 
Sifuna ukwazi ukuba zibakho kangakanani na iingxaki zokungamelani namachiza (i-ADR) 
kubantwana abalaliswe kwiSibhedlele saseTygerberg. Sifuna nokwazi ukuba ingaba wena wakhe 
wanayo na ingxaki yokungamelani namachiza kwaye kukwenze wagula njani oko. Iingxaki 
zokungamelani namachiza zizo naziphi na iimpembelelo ezingafunekiyo, zokwenza ungakhululeki 
okanye ubesengozini xa usebenzise amayeza (ichiza). Umzekelo, umntu anganerhashalala emva 
kokusebenzisa amayeza. 
 
Ngubani owenza uphando? 
 
NguGqr Memela Makiwane wesibhedlele saseTygerberg nakwiYunivesithi yaseStellenbosch. 
 
Kuza kwenzeka ntoni kum kolu phononongo? 
Ukuba uyavuma ukuba kolu phononongo, uGqr Makiwane uza kujonga iingxelo zakho zasesibhedlele 
neziphumo zovavanyo lwakho ajonge ukuba ingaba uguliswe kuba unengxaki yokungamelani namachiza, 
ufumene ingxaki yokungamelani namayeza ngoku usesibhedlele okanye ungekho sesibhedlele. Ukuba 
uGqr Makiwane ufumanisa ingxaki yokungamelani namachiza uza kuxelela u(oo)gqirha okunyangayo. 
Uza kuba yinxalenye yolu phononongo ude uphume esibhedlele ugoduke ngaphandle kokuba 
utshintsha iingqondo zakho ukhethe ukuyeka ukuba kolu phononongo ngeli xesha usesesibhedlele. 
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Ingaba ikhona into eza kwenzeka kum? 
Hayi. Olu phando lujonga kuphela okuqheleke ukwenzeka kubantwana abafumana unyango 
esibhedlele. 
Ingaba ikhona into entle enokwenzeka kum? 
Ewe. Uza kuxelelwa ukuba unengxaki yokungamelani namachiza okanye awunayo.  
Ingaba ukhona umntu oza kundazi ukuba ndikolu phononongo? 
Ngoogqirha kuphela abakunyangayo nogqirha owenza uphononongo abaza kukwazi ukuba ukolu 
phononongo. Xa lugqityiwe uphando, abanye oogqirha baza kuxelelwa oko kufunyanisiweyo 
kodwa akukho namnye oza kukwazi ukuba ukolu phononongo. Oku kwenzeka kuba akukho gama 
lamntu lifakwayo xa kuchazelwa abanye oogqirha oko kuye kwafunyaniswa luphando. 
 
Ndingathetha nabani ngolu phononongo?.  
NoGqr Memela Makiwane 
Umnxeba: 0219389335 
I-imeyile: Makiwane@sun.ac.za 
Ukuba andifuni kuyenza le nto? 
Ungatsho ukuba awufuni kuba kolu phononongo kwaye akukho 
namnye onokukunyanzela. Nokuba ungathi ewe namhlanje, 
ungayitshintsha ingqondo yakho nanini na ngokuchaza nje. Oko akuzi 
kukufaka engxakini. Kwaye oko akuzi kwenza nabani na ayitshintshe 
indlela akunceda ngayo esibhedlele. 
Uyaluqonda olu phando kwaye unomdla wokuba kulo na?   
EWE  HAYI 
 
Uyazazi ukuba ungaphuma kolu phononongo nanini na? 
EWE  HAYI 
 
 
____________________________________   ________________________ 
Igama kunye/okanye nokutyikitya koMntwana   Umhla 
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Approval Notice
Response to Modifications- (New Application)
05-Nov-2015
Makiwane, Memela MM
Ethics Reference #: S15/08/171
Title: Adverse drug reactions in paediatric in-patients in a South African tertiary hospital: A prospective observational study.
Dear Dr Memela Makiwane,
The Response to Modifications - (New Application) received on 19-Oct-2015, was reviewed by members of Health Research Ethics Committee 1
via Expedited review procedures on 04-Nov-2015 and was approved.
Please note the following information about your approved research protocol:
Protocol Approval Period: 04-Nov-2015 -04-Nov-2016
Please remember to use your protocol number (S15/08/171) on any documents or correspondence with the HREC concerning your research protocol.
Please note that the HREC has the prerogative and authority to ask further questions, seek additional information, require further modifications, or
monitor the conduct of your research and the consent process.
After Ethical Review:
Please note a template of the progress report is obtainable on www.sun.ac.za/rds and should be submitted to the Committee before the year has expired.
The Committee will then consider the continuation of the project for a further year (if necessary). Annually a number of projects may be selected
randomly for an external audit.
Translation of the consent document to the language applicable to the study participants should be submitted.
Federal Wide Assurance Number: 00001372
Institutional Review Board (IRB) Number: IRB0005239
The Health Research Ethics Committee complies with the SA National Health Act No.61 2003 as it pertains to health research and the United States
Code of Federal Regulations Title 45 Part 46. This committee abides by the ethical norms and principles for research, established by the Declaration of
Helsinki, the South African Medical Research Council Guidelines as well as the Guidelines for Ethical Research: Principles Structures and Processes
2004 (Department of Health).
Provincial and City of Cape Town Approval
Please note that for research at a primary or secondary healthcare facility permission must still be obtained from the relevant authorities (Western Cape
Department of Health and/or City Health) to conduct the research as stated in the protocol. Contact persons are Ms Claudette Abrahams at Western
Cape Department of Health (healthres@pgwc.gov.za Tel: +27 21 483 9907) and Dr Helene Visser at City Health (Helene.Visser@capetown.gov.za Tel:
+27 21 400 3981). Research that will be conducted at any tertiary academic institution requires approval from the relevant hospital manager. Ethics
approval is required BEFORE approval can be obtained from these health authorities.
We wish you the best as you conduct your research.
For standard HREC forms and documents please visit: www.sun.ac.za/rds
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Investigator Responsibilities
Protection of Human Research Participants
Some of the responsibilities investigators have when conducting research involving human participants are listed below:
1.Conducting the Research. You are responsible for making sure that the research is conducted according to the HREC approved research protocol. You
are also responsible for the actions of all your co-investigators and research staff involved with this research.
2.Participant Enrolment. You may not recruit or enrol participants prior to the HREC approval date or after the expiration date of HREC approval. All
recruitment materials for any form of media must be approved by the HREC prior to their use. If you need to recruit more participants than was noted
in your HREC approval letter, you must submit an amendment requesting an increase in the number of participants.
3.Informed Consent. You are responsible for obtaining and documenting effective informed consent using only the HREC-approved consent documents,
and for ensuring that no human participants are involved in research prior to obtaining their informed consent. Please give all participants copies of the
signed informed consent documents. Keep the originals in your secured research files for at least fifteen (15) years.
4.Continuing Review. The HREC must review and approve all HREC-approved research protocols at intervals appropriate to the degree of risk but not
less than once per year. There is no grace period. Prior to the date on which the HREC approval of the research expires, it is your responsibility to
submit the continuing review report in a timely fashion to ensure a lapse in HREC approval does not occur. If HREC approval of your research
lapses, you must stop new participant enrolment, and contact the HREC office immediately.
5.Amendments and Changes. If you wish to amend or change any aspect of your research (such as research design, interventions or procedures, number
of participants, participant population, informed consent document, instruments, surveys or recruiting material), you must submit the amendment to the
HREC for review using the current Amendment Form. You may not initiate any amendments or changes to your research without first obtaining
written HREC review and approval. The only exception is when it is necessary to eliminate apparent immediate hazards to participants and the HREC
should be immediately informed of this necessity.
6.Adverse or Unanticipated Events. Any serious adverse events, participant complaints, and all unanticipated problems that involve risks to participants
or others, as well as any research-related injuries, occurring at this institution or at other performance sites must be reported to the HREC within five (5)
days of discovery of the incident. You must also report any instances of serious or continuing problems, or non-compliance with the HRECs
requirements for protecting human research participants. The only exception to this policy is that the death of a research participant must be reported in
accordance with the Stellenbosch Universtiy Health Research Ethics Committee Standard Operating Procedures www.sun025.sun.ac.za/portal
/page/portal/Health_Sciences/English/Centres%20and%20Institutions/Research_Development_Support/Ethics/Application_package All reportable
events should be submitted to the HREC using the Serious Adverse Event Report Form.
7.Research Record Keeping. You must keep the following research-related records, at a minimum, in a secure location for a minimum of fifteen years: the
HREC approved research protocol and all amendments; all informed consent documents; recruiting materials; continuing review reports; adverse or
unanticipated events; and all correspondence from the HREC
8.Reports to the MCC and Sponsor. When you submit the required annual report to the MCC or you submit required reports to your sponsor, you
must provide a copy of that report to the HREC. You may submit the report at the time of continuing HREC review.
9.Provision of Emergency Medical Care. When a physician provides emergency medical care to a participant without prior HREC review and approval,
to the extent permitted by law, such activities will not be recognised as research nor will the data obtained by any such activities should it be used in
support of research.
10.Final reports. When you have completed (no further participant enrolment, interactions, interventions or data analysis) or stopped work on your
research, you must submit a Final Report to the HREC.
11.On-Site Evaluations, MCC Inspections, or Audits. If you are notified that your research will be reviewed or audited by the MCC, the sponsor, any
other external agency or any internal group, you must inform the HREC immediately of the impending audit/evaluation.
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Annexure: Conference abstract presentations: 
Conference Venue Date  Outcome 




Misty Hills Hotel and 
Conference Centre, 
Muldersdrift, Gauteng. 
5 – 8 October 
2016 
Presentation won 





Annual Academic Day 
Stellenbosch University 
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Participated in the 60th Annual Academic Day, Aug. 11, 2016




T4 Non-communicable Diseases Session 1 1
T7 Maternal and Child Health Session 2 1
T7 Maternal and Child Health Session 3 1
Main Programme 1
TOTAL 4
   
     
Prof. Nico C Gey van Pittius
Vice Dean: Research
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